PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.
Physiology-based pharmacokinetic (PBPK) modelling has been extensively used to quantitatively translate in vitro data and evaluate temporal effects from drug-drug interactions (DDIs), arising due to reversible enzyme and transporter inhibition, irreversible time-dependent inhibition, enzyme induction, and/or suppression. PBPK modelling has now gained reasonable acceptance with the regulatory authorities for the Cytochrome-P450-mediated DDIs and is routinely used. However, the application of PBPK for transporter-mediated DDIs (tDDI) in drug development is relatively uncommon. Since the predictive performance of PBPK models for tDDI is not well established, here we represent and discuss examples of PBPK analyses included in regulatory submission (FDA, EMA, and PMDA) across various tDDI. The goal of this collaborative effort (involving scientists representing 17 pharmaceutical companies in the Consortium and from academia) is to reflect on the use of current databases and models to address tDDIs. This challenge the common perceptions on applications of PBPK for tDDI and further delve into the requirements to improve such PBPK predictions. This review provides a reflection on the current trends in PBPK modelling for tDDIs and provides a framework to promote continuous use, verification and improvement in industrialisation of the transporter PBPK modelling.